PT - JOURNAL ARTICLE AU - Toro, Ayelen AU - Lage-Vickers, Sofia AU - Bizzotto, Juan AU - Vilicich, Felipe AU - Sabater, Agustina AU - Pascual, Gaston AU - Ledesma-Bazan, Sabrina AU - Sanchis, Pablo AU - Ruiz, Maria S. AU - Arevalo, Ana P. AU - Porfido, Jorge L. AU - Seniuk, Rocio AU - Labanca, Estefania AU - Anselmino, Nicolas AU - Navone, Nora AU - Alonso, Daniel F. AU - Vazquez, Elba AU - Crispo, Martina AU - Cotignola, Javier AU - Gueron, Geraldine TI - Pin-pointing the key hubs in the IFN-γ pathway responding to SARS-CoV-2 infection AID - 10.1101/2022.07.22.22277931 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.22.22277931 4099 - http://medrxiv.org/content/early/2022/07/23/2022.07.22.22277931.short 4100 - http://medrxiv.org/content/early/2022/07/23/2022.07.22.22277931.full AB - Interferon gamma may be a potential adjuvant immunotherapy for COVID-19 patients. In this work, we assessed gene expression profiles associated with the IFN-γ pathway in response to SARS-CoV-2 infection. Employing a case-control study from SARS-CoV-2 positive and negative patients, we identified IFN-γ-associated pathways to be enriched in positive patients. Bioinformatics analyses showed upregulation of MAP2K6, CBL, RUNX3, STAT1 and JAK2 in COVID-19 positive vs. negative patients. A positive correlation was observed between STAT1/JAK2, which varied alongside the patient’s viral load. Expression of MX1, MX2, ISG15 and OAS1 (4 well-known IFN-stimulated genes (ISGs)) displayed upregulation in COVID-19 positive vs. negative patients. Integrative analyses showcased higher levels of ISGs which were associated with increased viral load and STAT1/JAK2 expression. Confirmation of ISGs up-regulation was performed in vitro using the A549 lung cell line treated with Poly(I:C), a synthetic analog of viral double-stranded RNA; and in different pulmonary human cell lines and ferret tracheal biopsies infected with SARS-CoV-2. A pre-clinical murine model of coronavirus infection confirmed findings displaying increased ISGs in the liver and lungs from infected mice. Altogether, these results demonstrate the role of IFN-γ and ISGs in response to SARS-CoV-2 infection, highlighting alternative druggable targets that can boost the host response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion (ANPCyT), Argentina: PICT 2019-03215 CONICET.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GSE152075I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.